Compare
Tarsus Pharmaceuticals, Inc. vs Twist Bioscience Corp vs Immunocore Holdings plc vs ADMA Biologics, Inc.
| Latest fiscal year | Tarsus Pharmaceuticals, Inc. TARS | Twist Bioscience Corp TWST | Immunocore Holdings plc IMCR | ADMA Biologics, Inc. ADMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $451.36M | $459.43M | $400.02M | $510.17M |
| Revenue growth (YoY) | +146.7% | +22.0% | +29.0% | +19.6% |
| Gross margin | n/a | 52.4% (computed) | n/a | 57.4% |
| Operating margin | -15.7% | -30.4% | -11.3% | 37.5% |
| Net margin | -14.7% | -28.3% | -8.9% | 28.8% |
| Net income | -$66.42M | -$130.20M | -$35.51M | $146.93M |
| EPS (Diluted) | -$1.59 | -$2.08 | -$0.71 | $0.60 |
| Operating cash flow | -$12.45M | -$41.43M | -$10.71M | $50.40M |
| Free cash flow | -$22.31M | -$89.01M | -$15.05M | $27.82M |
| Cash & equivalents | $183.64M | $533.99M | $467.71M | $87.63M |
| Total assets | $562.16M | $1.12B | $1.07B | $624.24M |
| Total liabilities | $218.73M | $233.79M | $686.24M | $146.92M |
| Shareholders' equity | $343.43M | $888.02M | $381.03M | $477.32M |
| Return on year-end equity | -19.3% | -14.7% | -9.3% | 30.8% |
| Shares outstanding | 42.55M | 67.81M | 50.69M | 237.87M |
Revenue, most recent five fiscal years
| Fiscal year | Tarsus Pharmaceuticals, Inc. | Twist Bioscience Corp | Immunocore Holdings plc | ADMA Biologics, Inc. |
|---|---|---|---|---|
| Latest | $451.36M Ended 2025-12-31 | $459.43M Ended 2026-09-30 | $400.02M Ended 2025-12-31 | $510.17M Ended 2025-12-31 |
| 1 year earlier | $182.95M Ended 2024-12-31 | $376.57M Ended 2025-09-30 | $310.20M Ended 2024-12-31 | $426.45M Ended 2024-12-31 |
| 2 years earlier | $17.45M Ended 2023-12-31 | $312.97M Ended 2024-09-30 | $249.43M Ended 2023-12-31 | $258.21M Ended 2023-12-31 |
| 3 years earlier | $25.82M Ended 2022-12-31 | $245.11M Ended 2023-09-30 | $174.36M Ended 2022-12-31 | $154.08M Ended 2022-12-31 |
| 4 years earlier | $57.03M Ended 2021-12-31 | $203.56M Ended 2022-09-30 | $36.48M Ended 2021-12-31 | $80.94M Ended 2021-12-31 |